Extracorporeal Treatment of Intoxications Anne-Corne´Lie J.M

Total Page:16

File Type:pdf, Size:1020Kb

Extracorporeal Treatment of Intoxications Anne-Corne´Lie J.M Extracorporeal treatment of intoxications Anne-Corne´lie J.M. de Pont Purpose of review Introduction The purpose of this article is to provide the critical care Although intoxication is a common problem in adult and clinician with a comprehensive review of the indications for pediatric medicine, serious morbidity is unusual. In 2004, extracorporeal elimination of toxic substances, to only 3% of all toxic exposures reported to the Toxic summarize the different techniques and the intoxications for Exposure Surveillance System of the American Associ- which these techniques are suitable. ation of Poison Centers were treated in an ICU and in only Recent findings 0.05% extracorporeal treatment was needed [1]. Extracor- In the last year, several excellent reviews about toxicological poreal treatment, however, may be lifesaving in victims topics have been published. These reviews focused on of poisoning, especially when natural elimination intoxications in children, the approach of the patient with an mechanisms are impaired. This article reviews the charac- unknown overdose, management of intoxications with teristics of different extracorporeal techniques and sum- salicylates, b-blockers and calcium antagonists and liver marizes the intoxications for which they are suitable. support systems. Important developments include the use of high-flux, high-efficiency membranes and albumin dialysis Indication using the molecular adsorbent recirculating system The use of extracorporeal techniques to remove toxins is (MARS). This system offers possibilities for the removal of justified if there is an indication of severe toxicity (Table 1) protein-bound substances such as diltiazem, phenytoin and and if the total body elimination of the toxin can be theophylline. increased by 30% or more by using an extracorporeal Summary technique [2]. Whether extracorporeal removal is possible Although large randomized controlled trials are scarce in the depends on characteristics of the toxin itself and of the field of toxicology, the treatment of intoxications is elimination technique used (Table 2). As the majority of becoming more and more evidence based. This review reported toxic exposures occur in children of less than summarizes the current knowledge and recommendations 6 years old [3], it is important to know which substances concerning the extracorporeal treatment of intoxications are lethal for children, even in low doses [4,5]. These and discusses new developments in the field, such as the substances are summarized in Table 3. use of high-flux, high-efficiency membranes and albumin dialysis. Techniques available for extracorporeal removal of toxins Keywords The extracorporeal techniques most frequently employed hemodialysis, hemofiltration, hemoperfusion, intoxication, for the removal of toxins are hemodialysis, continuous poisoning hemofiltration techniques, hemoperfusion and the molecular adsorbent recirculating system (MARS). Curr Opin Crit Care 13:668–673. ß 2007 Wolters Kluwer Health | Lippincott Williams & Wilkins. Hemodialysis Adult Intensive Care Unit, Academic Medical Center, University of Amsterdam, During hemodialysis, toxins and other substances are The Netherlands cleared from the blood by diffusion across a semiperme- Correspondence to Anne-Corne´lie J.M. de Pont, Adult Intensive Care Unit, C3-327, able membrane down a concentration gradient from blood Academic Medical Center, Meibergdreef 9, NL-1105 AZ Amsterdam, The Netherlands into dialysate. In order to be removed by hemodialysis, the Tel: +31 20 5669111 ext 59229; fax: +31 20 5669568; toxic substance must be water soluble and must have a low e-mail: [email protected] molecular weight, low protein binding and a low volume of Current Opinion in Critical Care 2007, 13:668–673 distribution (Table 2). During hemodialysis, the clearance Abbreviation of a toxic substance depends on membrane surface area MARS molecular adsorbent recirculating system and type, as well as on blood and dialysate flow rates. The larger the membrane surface, the greater the amount of toxin removed. Newer high-flux membranes can also ß 2007 Wolters Kluwer Health | Lippincott Williams & Wilkins 1070-5295 remove high-molecular weight substances. Increasing blood and dialysate flow rates can increase the concen- tration gradient between blood and dialysate, thus opti- mizing the rates of diffusion and elimination. The major drawback of hemodialysis is the risk of rebound toxicity 668 Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Extracorporeal treatment of intoxications de Pont 669 Table 1 Indications of severe toxicity Table 3 Substances able to kill children at low doses (1) Ingested quantity associated with severe toxicity Calcium antagonists (2) Ingestion of a toxin with serious delayed effects Camphor (3) Natural removal mechanism impaired Clonidine and other imidazolines (4) Clinical condition deteriorating Lomotil (diphenoxylate/atropine) (5) Clinical evidence of severe toxicity: hypotension, coma, Opiates metabolic acidosis, respiratory depression, dysrhythmias Salicylates or cardiac decompensation Sulfonylureas Toxic alcohols Adapted from Orlowski et al. [2]. Tricyclic antidepressants Adapted from Michael and Sztajnkrycer [5]. Table 2 Necessary properties for extracorporeal removal by three different techniques Hemodialysis Hemofiltration Hemoperfusion Hemoperfusion Solubility water water water or lipid During hemoperfusion, the blood passes through a Molecular weight <500 Da <40 000 Da <40 000 Da cartridge containing a sorbent material able to adsorb Protein binding low (<80%) low low or high Volume of distribution <1 l/kg <1 l/kg <1 l/kg the toxin. There are three types of sorbents: charcoal- Endogenous clearance <4 ml/min/kg <4 ml/min/kg <4 ml/min/kg based sorbents, synthetic resins and anion exchange resins. Distribution time short longer short In order to be removed by hemoperfusion, the toxic Adapted from Orlowski et al. [2]. substance must have binding affinity to the sorbent in the cartridge and a low volume of distribution (Table 2). after cessation of the treatment, due to redistribution of Charcoal efficiently removes molecules in the 1000– the toxin. 1500 kDa range, but does not remove protein-bound mol- ecules [7]. Resins are more effective in the removal of Continuous techniques protein-bound and lipid-soluble molecules. Despite their In continuous hemofiltration techniques such as continu- efficacy, the use of hemoperfusion cartridges has declined ous venovenous hemofiltration (CVVH) and continuous over the last 20 years, due to limitations of their indications venovenous hemodiafiltration (CVVHD), the blood and shelf life. Moreover, hemoperfusion is technically passes through large pore hollow fibres, allowing the more difficult to perform than hemodialysis, and convective removal of molecules up to 40 kDa. The lacks the possibility of correcting acid–base, fluid and advantages of continuous techniques are their applica- electrolyte abnormalities [8]. bility in hemodynamically unstable patients and the prolonged duration of therapy, minimizing the risk of a Molecular adsorbent recirculating system rebound effect [6]. The disadvantage of continuous tech- MARS is a blood purification system, aimed at removing niques is their lower clearance compared with hemodia- albumin-bound toxic molecules [9,10]. It consists of lysis. In postdilutional hemofiltration, the clearance is three serial extracorporeal circuits: a blood circuit, an equal to the ultrafiltrate flow rate, which is usually no albumin detoxification circuit and a hemodialysis circuit more than 4 l/h or 67 ml/min, whereas with hemodialysis a (Fig. 1) [11]. The patient’s blood passes the blood com- clearance up to 500 ml/min can be achieved [2]. partment of a high-flux dialyzer, where albumin flows Figure 1 Molecular Adsorbent Recirculating System (MARS) circuit Q-albumin Q-dialysate Blood pump Bicarbonate PAE Low-flux buffered dialyzer dialysate Adsorption columns MARS- module Charcoal Albumin pump Q-blood Ion-exchange PAA Blood circuit Albumin circuit Single pass dialysis Reprinted with permission from Covic et al. [11]. Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 670 Renal system through the dialysate compartment in a countercurrent volume of 0.6–0.9 l/kg body weight and it is not protein fashion. Protein-bound and water soluble substances can bound, which makes it an ideal substance to be removed by enter the albumin circuit by means of diffusion. The hemodialysis. With hemodialysis, an extraction ratio of albumin circuit contains two filters, an activated charcoal 90% and a clearance ranging from 63 to 114 ml/min is filter which absorbs the toxins and an anion-exchange achieved, making it the treatment of choice for extracor- resin filter to cleanse the albumin. Finally, the albumin poreal lithium removal [17]. Hemodialysis is even more passes through the blood compartment of a second effective in removing lithium than the kidney itself, as dialyzer, where small molecules are filtered down a 70–80% of lithium filtered by the kidney is reabsorbed in concentration gradient to bicarbonate dialysate [12]. the proximal tubule. Hemodialysis should be started in Although the efficacy of MARS in the removal of cases of central nervous system abnormalities such as protein-bound drugs such as diltiazem, phenytoin and confusion, stupor, coma or seizures. A negative anion theophylline has been demonstrated in case reports, the gap and an elevated osmolar
Recommended publications
  • Interaction Between Renal Replacement Therapy And
    rren Cu t R y: es Romano, Surgery Curr Res 2014, 4:1 r e e a g r r c u h DOI: 10.4172/2161-1076.1000154 S Surgery: Current Research ISSN: 2161-1076 Review Article Open Access Interaction between Renal Replacement Therapy and Extracorporeal Membrane Oxygenation Support Thiago Gomes Romano* Assistant Teaching Professor for the Discipline of Nephrology, ABC Medical School Medical Intensivist at Hospital, Sírio-Libanês, Brazil Abstract Extracorporeal Membrane Oxygenation (ECMO) is one of the designations used for extracorporeal circuits capable of oxygenation, carbon dioxide removal and, eventually, circulatory support. Acute respiratory distress syndrome with severe hypoxemia or acidemia with high carbon dioxide levels in a scenario of low pulmonary tidal volume is its mainly indication. Acute Kidney Injury (AKI) and its complications such as volume overload and azotemia are common in this situation; some epidemiological studies have shown that around 78% of the patients demanding ECMO therapy develop AKI. Therefore, renal replacement therapy is required in about 50% of those cases. This papers aims to explain the concept of the ECMO circuit and the ways continuous renal replacement therapy (CRRT) can be instituted in critical ill patients who need ECMO. Keywords: ECMO; Renal replacement therapy; Dialysis internal jugular or femoral vein with the return placed in the femoral artery. Additionally, a jugular-carotid cannulation is one option despite Introduction the potential for neurological injury. In cases exclusively intended for Extracorporeal Membrane Oxygenation (ECMO) is one of the ventilatory support [venovenous (VV) ECMO], cannulation can be designations used for extracorporeal circuits capable of oxygenation, placed femoro-jugular, jugular-femoral or femoral-femoral depending carbon dioxide (CO ) removal and, eventually, circulatory support.
    [Show full text]
  • Management of Acute Clonidine Poisoning in Adults: the Role of Resin Hemoperfusion
    Management of Acute Clonidine Poisoning in Adults: The Role of Resin Hemoperfusion Shanshan Fang Department of Nephrology, 307 Hospital Bo Han Department of Nephrology, 307 Hospital Xiaoling Liu Department of Nephrology, 307 Hospital Dan Mao Department of Nephrology, 307 Hospital Chengwen Sun Laboratory of Poisonous Substance Detection, 307 Hospital Zhi Chen Department of Nephrology, 307 Hospital Ruimiao Wang Department of Nephrology, 307 Hospital Xishan Xiong ( [email protected] ) Aliated Hengsheng Hospital of the Southern Medical University https://orcid.org/0000-0002-8557- 8025 Methodology Keywords: clonidine poisoning, adrenergic alpha-agonists, bradycardia, hemoperfusion, hypotension Posted Date: September 21st, 2020 DOI: https://doi.org/10.21203/rs.3.rs-76660/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Clonidine poisoning in adults is rare. An observational retrospective study including 102 adults with clonidine poisoning was conducted. 57 patients with relatively mild conditions were placed in the local emergency departments (EDs) for clinical observation, while the remaining 45 were transferred to the tertiary hospital for intensive treatment, of whom 9 were given supportive care only and 36 were given hemoperfusion (HP), as well as similar supportive treatment. The main symptoms of these cases were: sleepiness, dizziness, fatigue, headache, inarticulacy, tinnitus and dry mouth. Physical examination showed hypotension, bradycardia and shallow and slow breathing. Serum and urine clonidine concentrations were signicantly elevated24.4 ng/ml, 313.2 ng/ml, respectively. All cases slowly returned to their baseline state over 48 to 96 hours, which is co-related with the drawn of serum clonidine level.
    [Show full text]
  • Emergency Medical Services Program Policies – Procedures – Protocols
    Emergency Medical Services Program Policies – Procedures – Protocols Protocols Table of Contents GENERAL PROVISIONS ................................................................................................ 3 DESTINATION DECISION SUMMARY-METRO BAKERSFIELD AREA ........................ 5 DETERMINATION OF DEATH ..................................................................................... 12 101 AIRWAY OBSTRUCTION ...................................................................................... 16 102 ALTERED LEVEL OF CONSCIOUSNESS ............................................................ 18 103 ALLERGIC REACTION/ANAPHYLAXIS ................................................................ 20 104 ASYSTOLE/ PULSELESS ELECTRICAL ACTIVITY ............................................. 22 105 BITES STINGS ENVENOMATION ......................................................................... 24 106 BRADYCARDIA ..................................................................................................... 26 107 BRIEF RESOLVED UNEXPLAINED EVENT ......................................................... 29 108 BURNS ................................................................................................................... 32 109 CHEMPACK ........................................................................................................... 35 110 CHEST PAIN OR ACUTE CORONARY SYNDROME ........................................... 37 111 CHEST TRAUMA ..................................................................................................
    [Show full text]
  • Overview of Complications of Hemodialysis Access
    Update on Hemodialysis Access Raymond J. Holmes, MD April 4th, 2019 Presenter Disclosure Information Raymond J. Holmes, MD The Cardiovascular Care Group FINANCIAL DISCLOSURE: Nothing to disclose UNLABELED/UNAPPROVED USES DISCLOSURE: No unlabeled and or unapproved off-label use of products or devices will be discussed in this presentation Update on Hemodialysis Access Surgery • Overview: K-DOQI and Fistula First • Strategy for sequential access placement • AV fistula, AV graft, basilic vein transposition, HeRO device • Endovascular Intervention • Complications In the Beginning… Belding Scribner 1921-2003 Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula Michael J. Brescia, M.D., James E. Cimino, M.D., Kenneth Appel, M.D. and Baruch J. Hurwich, M.D. NEJM 275:1089-1092, 1966. James E. Cimino (1928-2010) What is the best access for hemodialysis? • 53 years after initial description of the AV fistula, it still remains the best access for hemodialysis Michael J. Brescia, M.D., James E. Cimino, M.D., Kenneth Appel, M.D. and Baruch J. Hurwich, M.D. NEJM 275:1089-1092, 1966. DOQI Guidelines • Developed by National Kidney Foundation. (www.kidney.org) • Common sense, common practice • Some “evidence” based; some opinion based. • Careful disclaimers not to be “standard of care” – However, widely adapted as “standard of care”. Guidelines on topics for management of patients with chronic kidney disease including vascular access •Clinical Practice Guidelines for Vascular Access, Update 2006 •Guideline 1. Patient Preparation for Permanent Hemodialysis Access •Guideline 2. Selection and Placement of Hemodialysis Access •Guideline 3. Cannulationof Fistulae and Grafts and Accession of Hemodialysis Catheters and Port Catheter Systems •Guideline 4.
    [Show full text]
  • Effect of Hemoperfusion Using Polymyxin B-Immobilized Fiber on IL-6, HMGB-1, and IFN Gamma in a Neonatal Sepsis Model
    0031-3998/05/5802-0309 PEDIATRIC RESEARCH Vol. 58, No. 2, 2005 Copyright © 2005 International Pediatric Research Foundation, Inc. Printed in U.S.A. Effect of Hemoperfusion Using Polymyxin B-Immobilized Fiber on IL-6, HMGB-1, and IFN Gamma in a Neonatal Sepsis Model MOHAMED HAMED HUSSEIN, TAKENORI KATO, TAKAHIRO SUGIURA, GHADA A. DAOUD, SATOSHI SUZUKI, SUMIO FUKUDA, HISANORI SOBAJIMA, INEKO KATO, AND HAJIME TOGARI Department of Pediatrics, Neonatology and Congenital Disorders [M.H.H., T.K., T.S., G.A.D., S.F., H.S., I.K., H.T.], Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Department of Pediatrics [S.S.], Nagoya City Johoku Hospital, Nagoya, Japan, Neonatal Intensive Care Unit [M.H.H.], Pediatric Hospital, Cairo University, Cairo, Egypt, Maternal and Child Health Department [M.H.H., G.A.D.], VACSERA, Giza, Egypt ABSTRACT To evaluate effects of polymyxin B direct hemoperfusion at 6 h. IFN-␥ was only detected in the control group at 9 h. (PMX-DHP) on a neonatal sepsis cecal ligation and perforation Survival times in the PMX-DHP group were longer than in the (CLP) model, in 24 anesthetized and mechanically ventilated control. Thus, PMX-DHP improved septic shock in a neonatal 3-d-old piglets, 16 were assigned to CLP and an arteriovenous septic model. (Pediatr Res 58: 309–314, 2005) extracorporeal circuit from 3 h until 6 h post-CLP, with a PMX-column in PMX-DHP–treated group (8 piglets) and 8 as sham. Plasma lipopolysaccharide (LPS) was measured at before Abbreviations CLP and at 3 and 9 h.
    [Show full text]
  • 615.9Barref.Pdf
    INDEX Abortifacient, abortifacients bees, wasps, and ants ginkgo, 492 aconite, 737 epinephrine, 963 ginseng, 500 barbados nut, 829 blister beetles goldenseal blister beetles, 972 cantharidin, 974 berberine, 506 blue cohosh, 395 buckeye hawthorn, 512 camphor, 407, 408 ~-escin, 884 hypericum extract, 602-603 cantharides, 974 calamus inky cap and coprine toxicity cantharidin, 974 ~-asarone, 405 coprine, 295 colocynth, 443 camphor, 409-411 ethanol, 296 common oleander, 847, 850 cascara, 416-417 isoxazole-containing mushrooms dogbane, 849-850 catechols, 682 and pantherina syndrome, mistletoe, 794 castor bean 298-302 nutmeg, 67 ricin, 719, 721 jequirity bean and abrin, oduvan, 755 colchicine, 694-896, 698 730-731 pennyroyal, 563-565 clostridium perfringens, 115 jellyfish, 1088 pine thistle, 515 comfrey and other pyrrolizidine­ Jimsonweed and other belladonna rue, 579 containing plants alkaloids, 779, 781 slangkop, Burke's, red, Transvaal, pyrrolizidine alkaloids, 453 jin bu huan and 857 cyanogenic foods tetrahydropalmatine, 519 tansy, 614 amygdalin, 48 kaffir lily turpentine, 667 cyanogenic glycosides, 45 lycorine,711 yarrow, 624-625 prunasin, 48 kava, 528 yellow bird-of-paradise, 749 daffodils and other emetic bulbs Laetrile", 763 yellow oleander, 854 galanthamine, 704 lavender, 534 yew, 899 dogbane family and cardenolides licorice Abrin,729-731 common oleander, 849 glycyrrhetinic acid, 540 camphor yellow oleander, 855-856 limonene, 639 cinnamomin, 409 domoic acid, 214 rna huang ricin, 409, 723, 730 ephedra alkaloids, 547 ephedra alkaloids, 548 Absorption, xvii erythrosine, 29 ephedrine, 547, 549 aloe vera, 380 garlic mayapple amatoxin-containing mushrooms S-allyl cysteine, 473 podophyllotoxin, 789 amatoxin poisoning, 273-275, gastrointestinal viruses milk thistle 279 viral gastroenteritis, 205 silibinin, 555 aspartame, 24 ginger, 485 mistletoe, 793 Medical Toxicology ofNatural Substances, by Donald G.
    [Show full text]
  • Hemodialysis
    The Ohio State University Veterinary Medical Center Hemodialysis What is hemodialysis? Hemodialysis is a method of blood purification that This is most commonly performed in the acute setting removes blood from the body through a catheter (acute kidney injury) for animals but may also be elected and filters it through a dialyzer (artificial kidney). for patients with chronic kidney dysfunction. Hemodialysis is used to purify the blood by eliminating While acute kidney injury is the most common reason toxic metabolites, balancing electrolytes, and removing for performing hemodialysis, it can also be used to treat excess water that builds up when the kidneys are acute intoxications to enhance elimination of a toxin. unable to excrete it. Indications for Hemodialysis Acute Kidney Injury This is the most common indication for hemodialysis. 10-14 days of hospitalization and treatment. With acute This procedure should be considered when clinical kidney injury, the kidneys typically start to regain some uremia, hyperkalemia, acid/base disturbances, and function within this time period, but a lack of response fluid overload cannot be managed with conventional does not mean the kidneys will never recover. medical therapy. The best time to start hemodialysis There are instances when it may take up to four weeks is still unknown (even in human medicine), but starting to become dialysis independent. Patients are generally treatment sooner means fewer side effects from uremia. transitioned after the 10-14 days to outpatient treatments Thus, hemodialysis should be considered sooner rather to continue to provide time for the kidneys to recover. than later. Outpatient treatments allow families to play an active When hemodialysis is performed, pet owners should role in facilitating recovery.
    [Show full text]
  • Critical Care Nursing of Infants and Children Martha A
    University of Pennsylvania ScholarlyCommons Miscellaneous Papers Miscellaneous Papers 1-1-2001 Critical Care Nursing of Infants and Children Martha A. Q. Curley University of Pennsylvania, [email protected] Patricia A. Moloney-Harmon The Children's Hospital at Sinai Copyright by the author. Reprinted from Critical Care Nursing of Infants and Children, Martha A.Q. Curley and Patricia A. Moloney-Harmon (Editors), (Philadelphia: W.B. Saunders Co., 2001), 1,128 pages. NOTE: At the time of publication, the author, Martha Curley was affiliated with the Children's Hospital of Boston. Currently, she is a faculty member in the School of Nursing at the University of Pennsylvania. This paper is posted at ScholarlyCommons. http://repository.upenn.edu/miscellaneous_papers/4 For more information, please contact [email protected]. Please Note: The full version of this book and all of its chapters (below) can be found on ScholarlyCommons (from the University of Pennsylvania) at http://repository.upenn.edu/miscellaneous_papers/4/ Information page in ScholarlyCommons Full book front.pdf - Front Matter, Contributors, Forward, Preface, Acknowledgements, and Contents Chapter 1.pdf - The Essence of Pediatric Critical Care Nursing Chapter 2.pdf - Caring Practices: Providing Developmentally Supportive Care Chapter_3.pdf - Caring Practices: The Impact of the Critical Care Experience on the Family Chapter_4.pdf - Leadership in Pediatric Critical Care Chapter 5.pdf - Facilitation of Learning Chapter_6.pdf - Advocacy and Moral Agency: A Road Map for
    [Show full text]
  • UNDERSTANDING YOUR HEMODIALYSIS OPTIONS Hemodialysis Is a Treatment for Access People Whose Kidneys Are No Longer Involves Working
    UNDERSTANDINGUnderstanding YOUR HEMODIALYSISYour OPTIONS Hemodialysis Access Options This educational activity is supported by a donation by Amgen, Inc UNDERSTANDING YOUR HEMODIALYSIS OPTIONS Hemodialysis is a treatment for access people whose kidneys are no longer involves working. The treatment removes making a waste products and fluid from the connection blood using an artificial kidney between an machine. It is the most common artery and a treatment for people who have end- vein under stage renal disease (ESRD), or whose the skin. A kidneys no longer work. surgeon will make There are four types of hemodialysis your fistula treatment options. AAKP created this or graft brochure to explain each of your by sewing treatment options, and to show you one of your the pros and cons of each option. arteries to Mayo Clinic Foundation for one of your Education and Research veins. It’s CREATING AN ACCESS a simple medical procedure. Your surgeon Before you begin hemodialysis chooses which artery and vein to treatment, a surgeon must create connect depending on how fast your an access for the machine. Don’t be blood flows through the artery and afraid. Access for the machine will vein. be at a place on your body close to a vein and artery. It allows access A catheter is the other type of to your blood stream. Blood goes access. A catheter is a thin, flexible from your body through the access tube that can be put through a small and to the dialysis machine. Once hole in your body. A surgeon inserts inside the artificial kidney machine, the catheter through your skin into the machine cleans the blood and a large vein in the neck, chest or returns the clean blood back to groin.
    [Show full text]
  • A Case of Mushroom Poisoning with Russula Subnigricans: Development of Rhabdomyolysis, Acute Kidney Injury, Cardiogenic Shock, and Death
    CASE REPORT Nephrology http://dx.doi.org/10.3346/jkms.2016.31.7.1164 • J Korean Med Sci 2016; 31: 1164-1167 A Case of Mushroom Poisoning with Russula subnigricans: Development of Rhabdomyolysis, Acute Kidney Injury, Cardiogenic Shock, and Death Jong Tae Cho and Jin Hyung Han Mushroom exposures are increasing worldwide. The incidence and fatality of mushroom poisoning are reported to be increasing. Several new syndromes in mushroom poisoning Department of Internal Medicine, College of have been described. Rhabdomyolytic mushroom poisoning is one of new syndromes. Medicine, Dankook University, Cheonan, Korea Russula subnigricans mushroom can cause delayed-onset rhabdomyolysis with acute Received: 17 April 2015 kidney injury in the severely poisoned patient. There are few reports on the toxicity of R. Accepted: 6 June 2015 subnigricans. This report represents the first record of R. subnigricans poisoning with rhabdomyolysis in Korea, describing a 51-year-old man who suffered from rhabdomyolysis, Address for Correspondence: Jong Tae Cho, MD acute kidney injury, severe hypocalcemia, respiratory failure, ventricular tachycardia, Department of Internal Medicine, College of Medicine, cardiogenic shock, and death. Mushroom poisoning should be considered in the evaluation Dankook University, 201 Manghyang-ro, Dongnam-gu, Cheonan 31116, Korea of rhabdomyolysis of unknown cause. Furthermore, R. subnigricans should be considered E-mail: [email protected] in the mushroom poisoning with rhabdomyolysis. Keywords: Mushroom Poisoning; Rhabdomyolysis; Acute Kidney Injury; Respiratory Failure; Cardiogenic Shock INTRODUCTION in August, 2010 at the Jujak mountain located on the province of Jeollanam­do, the southern area of Korea. He was a bus driv­ More leisure time for hobbies, hiking, and trekking has led to er.
    [Show full text]
  • Ultrafiltration I Hemodialysis During Cardiopulmonary Bypass: a Case Report
    THE jOURNAL OF EXTRA-CORPOREAL TECHNOLOGY Case Report Ultrafiltration I Hemodialysis During Cardiopulmonary Bypass: A Case Report Scott D. Niles, BA, Robin G. Sutton, MS, CCP, Richard P. Embrey, MD University of Iowa Hospitals and Clinics, Iowa City, Iowa Keywords: cardiopulmonary bypass; hemodialysis, concurrent; technique; ultrafiltration. ABSTRACT Patient demographics for elective cardiovascular surgery have shifted toward older patients with more profound disease states. Cardiopulmonary bypass is complicated when the patient presents with end stage renal disease. Hemodialysis during cardiopulmonary bypass has been successfully employed to reduce the postoperative sequelae associated with cardiopulmo­ nary bypass. A patient with end stage renal disease who presented for coronary artery bypass grafting serves as the subject of this case report. Utilizing a modified technique previously described by Wiggins and Dearing, we describe successful intraoperative use of hemodialysis during cardiopulmonary bypass. Our experience suggests that hemodialysis during cardiopulmo­ nary bypass is an effective alternative to ultrafiltration and may prolong the time interval for resumption of postoperative dialysis regimens. Address correspondence to: Scott D. Niles University of Iowa Hospitals and Clinics Perfusion Technology Program Department of Surgery Division of Cardiothoracic Surgery 1600 JCP Iowa City, lA 52242 104 Volume 27, Number 2, June 1995 THE jOURNAL OF EXTRA-CORPOREAL TECHNOLOGY INTRODUCTION helping to resolve elevated BUN and creatinine levels. A hemodialysis circuit was constructed in parallel with the Population demographics in patients undergoing elective cardiopulmonary bypass circuit (Figure 1). A purge port on top cardiovascular surgery have undergone dramatic changes over of the arterial filter served as the blood source for an ultrafiltration the past twenty years, With a trend toward older patients with hemoconcentrator which then emptied into a venous reservoir bag.
    [Show full text]
  • Pattern and Epidemiology of Poisoning in the East African Region: a Literature Review
    Hindawi Publishing Corporation Journal of Toxicology Volume 2016, Article ID 8789624, 26 pages http://dx.doi.org/10.1155/2016/8789624 Review Article Pattern and Epidemiology of Poisoning in the East African Region: A Literature Review Dexter Tagwireyi,1 Patience Chingombe,1 Star Khoza,2 and Mandy Maredza3 1 Drug and Toxicology Information Service (DaTIS), School of Pharmacy, College of Health Sciences, University of Zimbabwe, P.O. Box A178, Avondale, Harare, Zimbabwe 2Department of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe, P.O. Box A178, Avondale, Harare, Zimbabwe 3School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa Correspondence should be addressed to Dexter Tagwireyi; [email protected] Received 19 July 2016; Accepted 19 September 2016 Academic Editor: Steven J. Bursian Copyright © 2016 Dexter Tagwireyi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The establishment and strengthening of poisons centres was identified as a regional priority at the first African regional meeting on the Strategic Approach to International Chemicals Management (SAICM) in June 2006. At this meeting, the possibility of a subregional poisons centre, that is, a centre in one country serving multiple countries, was suggested. The WHO Headquarters following consultation with counterparts at the WHO Regional Office for Africa (AFRO) and the SAICM Africa Regional Focal Point successfully submitted a proposal to the SAICM Quick Start Programme (QSP) Trust Fund Committee for a feasibility study into a subregional poisons centre in the Eastern Africa subregion.
    [Show full text]